

# Giulia Falconi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1292423/publications.pdf>

Version: 2024-02-01

32  
papers

440  
citations

686830

13  
h-index

794141

19  
g-index

35  
all docs

35  
docs citations

35  
times ranked

769  
citing authors

#	ARTICLE	IF	CITATIONS
1	Why methylation is not a marker predictive of response to hypomethylating agents. <i>Haematologica</i> , 2014, 99, 613-619.	1.7	61
2	Impairment of PI3K/AKT and WNT/ $\beta$ -catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016, 44, 75-83.e4.	0.2	42
3	Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 785-790.	3.3	33
4	Fanconi anemia gene variants in therapy-related myeloid neoplasms. <i>Blood Cancer Journal</i> , 2015, 5, e323-e323.	2.8	32
5	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. <i>American Journal of Hematology</i> , 2019, 94, 1091-1097.	2.0	25
6	What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms. <i>Blood</i> , 2021, 138, 749-757.	0.6	23
7	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. <i>Leukemia</i> , 2013, 27, 982-985.	3.3	22
8	The <i>BCL2L10</i> Leu21Arg variant and risk of therapy-related myeloid neoplasms and <i>de novo</i> myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2014, 55, 1538-1543.	0.6	22
9	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 865.	1.7	22
10	Clonal evolution in therapy-related neoplasms. <i>Oncotarget</i> , 2017, 8, 12031-12040.	0.8	22
11	SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. <i>Haematologica</i> , 2014, 99, e152-e153.	1.7	16
12	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1527-1530.	3.3	16
13	Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis. <i>Frontiers in Oncology</i> , 2022, 12, 871590.	1.3	16
14	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. <i>Cancers</i> , 2019, 11, 1373.	1.7	13
15	Therapy-related myeloid neoplasms: clinical perspectives. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5909-5915.	1.0	12
16	Mutational profile of ZBTB16 <sup>RARA</sup> -positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 3839-3847.	1.3	9
17	Longitudinal detection of <i>DNMT3A</i> <sup>R882H</sup> transcripts in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E120-E123.	2.0	7
18	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. <i>British Journal of Haematology</i> , 2022, 198, 103-113.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2019, 84, 106191.	0.4	5
20	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. <i>Biology</i> , 2021, 10, 128.	1.3	5
21	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 2942-2944.	0.6	4
22	Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. <i>Experimental Hematology</i> , 2014, 42, 731-733.	0.2	4
23	Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. <i>Molecular and Clinical Oncology</i> , 2017, 8, 463-465.	0.4	4
24	The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia. <i>Oncotarget</i> , 2017, 8, 84074-84085.	0.8	4
25	Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (<scp>MDS</scp>). <i>British Journal of Haematology</i> , 2019, 185, 954-957.	1.2	4
26	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91.	0.4	2
27	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. <i>British Journal of Haematology</i> , 2019, 186, e100-e103.	1.2	2
28	In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome. <i>Platelets</i> , 2021, 32, 378-382.	1.1	2
29	Expression Profile of Bone Marrow Mesenchymal Stromal Cells Isolated from Patients with Therapy-Related Myeloid Neoplasms. <i>Leukemia Research</i> , 2017, 55, S116-S117.	0.4	1
30	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2020, 61, 979-982.	0.6	1
31	Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy. <i>Blood</i> , 2020, 136, 19-20.	0.6	1
32	Unravelling Genetic Mechanisms of Erythrocytosis: A Real-Life Experience from a Single Center. <i>Blood</i> , 2018, 132, 3617-3617.	0.6	0